Pramipexole vs RAD-140
FDA Approved vs Emerging
synergistic Mechanism-based · 46% RAD-140 supports hormonal recovery from suppression caused by Pramipexole. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Pramipexole RAD-140
Weight 211.33 Da 393.83 Da
Half-life ~8 hours ~60 hours
Type Non-ergoline dopamine D3 receptor agonist Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
Pramipexole
01 Suppresses prolactin elevation caused by 19-nor anabolic steroids
02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
03 Generally cheaper and more widely available than cabergoline
04 FDA-approved with a well-characterized safety and pharmacokinetic profile
05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
06 Viable alternative when cabergoline cannot be sourced
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Side Effects
Pramipexole
Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
Pramipexole RAD-140
Status FDA Approved Emerging
References 5 studies 5 studies
Latest — July 2020
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.